$XBI $146.51 -0.5% 📉
Want to access our searchable database of over 900 catalysts and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
$NVAX +8% Announced results from ph 3 covid trial in UK and ph 2b trial in South Africa. see full results here
$SFE -2% & $TBIO +5% Initiate a ph 1/2 trial for MRT5500 against SARS-CoV-2. TBIO will receive $25M based on this milestone. source
$CFRX +4% BARDA contact awarded will provide funding for ph 3 DISRUPT study of exebacase for Staph a blood infections, a potentially registrational study as a basis for US approval. source
$AVEO +5% Collaboration with $BMS +1% to run a ph 3 trial of FOTIVDA + OPDIVO for advanced r/r renal cell carcinoma. source
$RUBY +34% Announced they will review initial data from ongoing ph 1/2 trial of RTX-240 in advanced solid tumors. source